<?xml version="1.0" encoding="UTF-8"?>
<p id="par0070">Based on experience with previous coronavirus infections, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), several treatment options have been proposed to manage patients with COVID-19 [
 <xref rid="bib0130" ref-type="bibr">26</xref>]. Some of these options have already proved their efficacy in in-vitro studies, and even in several clinical trials. Until the time of writing this manuscript, no single drug has globally been approved as treatment for COVID-19. However, emergency authorization was given on a national level in some countries like the USA and Europe for the use of Chloroquine (CQ)/ Hydroxychloroquine (HCQ) in certain cases. Chinese guidelines in their 7th edition also authorized other therapies like Lopinavir/Ritonavir and Ribavirin+/- IFN(α-2 β) [
 <xref rid="bib0035" ref-type="bibr">7</xref>,
 <xref rid="bib0110" ref-type="bibr">22</xref>,
 <xref rid="bib0135" ref-type="bibr">27</xref>,
 <xref rid="bib0140" ref-type="bibr">28</xref>]. Depending on the three clinical stages of COVID-19, we present the potential therapeutic options for each stage, taking into consideration in the same time that these propositions may potentially take a cumulative form where some potential treatments of stage I, as an example, may be used also in more advanced stages, while the opposite scenario may be, in our opinion, considered as risky (
 <xref rid="fig0005" ref-type="fig">Fig. 1</xref> ).
</p>
